Barbituric Acid

Barbituric Acid

SCHEMBL2453572

NCc1cc(Cl)c(O)c(Cl)c1.O=C1CC(=O)NC(O)=N1

nearest known ligand 0.32

Full drug profile on Sugi Atlas →

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
KLKB1 P03952 1/20 0.30
MELK Q14680 1/20 0.30
THRB P10828 1/20 0.30
CYP2D6 P10635 1/20 0.30
CYP2C9 P11712 1/20 0.30
TSHR P16473 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Barbituric Acid SCHEMBL2453574 0.81 THRB (0.34) KLKB1THRBCYP2D6CYP2C9TSHR
Barbituric Acid SCHEMBL45717 0.74
Barbituric Acid SCHEMBL20522064 0.73 SRC (0.32)
SCHEMBL12305705 0.73 THRB (0.52) THRBCYP2D6CYP2C9TSHR
Barbituric Acid SCHEMBL691401 0.70 SRC (0.33)
Barbituric Acid SCHEMBL8495242 0.70
Barbituric Acid SCHEMBL8492901 0.69 SRC (0.32)
Barbituric Acid SCHEMBL9571696 0.68 MEN1 (0.34)
Norepinephrine SCHEMBL7577671 0.67 BLM (0.59) THRBCYP2D6TSHR
Barbituric Acid SCHEMBL7529989 0.65 ITGB3 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8013019-B2 Sulfonamide derivatives for the treatment of diseases PFIZER INC (US) 2011-09-06 US disclosed
US-20100273758-A1 Sulfonamide Derivatives For The Treatment Of Diseases BROWN ALAN DANIEL 2010-10-28 US disclosed
US-7767715-B2 Sulfonamide derivatives for the treatment of diseases PFIZER INC (US) 2010-08-03 US disclosed
US-20090197912-A1 Sulfonamide Derivatives for the Treatment of Diseases BROWN ALAN DANIEL 2009-08-06 US disclosed
US-7528170-B2 Sulfonamide derivatives for the treatment of diseases PFIZER INC. (US) 2009-05-05 US disclosed
US-20080267970-A1 Sulfonamide Derivatives For The Treatment of Diseases BROWN ALAN DANIEL 2008-10-30 US disclosed
EP-1708991-B1 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES PFIZER LTD (GB) 2007-10-17 EP disclosed
US-7244766-B2 Sulfonamide derivatives for the treatment of diseases PFIZER INC (US) 2007-07-17 US disclosed
EP-1708991-A2 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES Pfizer Limited (GB) 2006-10-11 EP disclosed
WO-2005080313-A9 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES PFIZER LTD (GB) 2006-08-31 WO disclosed
WO-2005080313-A2 SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES PFIZER LIMITED (GB) 2005-09-01 WO disclosed
US-20050182091-A1 For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal PFIZER INC. 2005-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273758-A1 Sulfonamide Derivatives For The Treatment Of Diseases SULT2A1, STS, SULT1A1 KLKB1 2113/4885MELK 3864/4885THRB 3941/4885
US-20090197912-A1 Sulfonamide Derivatives for the Treatment of Diseases SULT2A1, STS, SULT1A1 KLKB1 2113/4885MELK 3864/4885THRB 3941/4885
US-20050182091-A1 For therapy of asthma or chronic obstructive pulmonary disease (COPD) in a mammal LTC4S, LTB4R2, LTB4R KLKB1 1059/4885MELK 2943/4885THRB 2049/4885
US-20080267970-A1 Sulfonamide Derivatives For The Treatment of Diseases SULT2A1, STS, SULT1A1 KLKB1 2113/4885MELK 3864/4885THRB 3941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.